BetaGlue Technologies SpA

BetaGlue Technologies can deliver a localized amount of energy via a simple, intra-operative, internal radiotherapy platform engineered to achieve maximum efficacy and much improved safety for the patients. A new anti-tumoral compound based on 90Y β-emitting microspheres, embedded in a bio-compatible matrix and delivered to target with a proprietary delivery system. Our technology is the first one to allow a highly controlled administration of radionuclides directly into the tumoral mass (or on the surgical bed following its resection). It achieves the highest efficacy where it is needed, while at the same time minimizing the risk of unwanted side effects, both locally and in the entire patient’s body. A global team of industry professionals with a track record in bringing innovation to market is developing a new technology in the loco-regional therapy of solid tumors, cleared as a medical device worldwide.